$1.18
Revenue is down for the last 4 quarters, 136.62M → 117.35M (in $), with an average decrease of 4.9% per quarter
Netprofit is down for the last 2 quarters, -99.81M → -192.18M (in $), with an average decrease of 92.5% per quarter
In the last 1 year, Idexx Laboratories, Inc. has given 30.4% return, outperforming this stock by 81.6%
In the last 3 years, Thermo Fisher Scientific, Inc. has given 40.1% return, outperforming this stock by 133.4%
0.85%
Downside
Day's Volatility :10.0%
Upside
9.23%
13.56%
Downside
52 Weeks Volatility :88.67%
Upside
86.89%
Period | Invitae Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -16.31% | 5.1% | -0.2% |
6 Months | -49.14% | -5.5% | -1.5% |
1 Year | -51.24% | 3.9% | -1.7% |
3 Years | -93.31% | 27.0% | 20.6% |
Market Capitalization | 328.6M |
Book Value | - $0.14 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -12.73 |
PEG Ratio | -0.51 |
Wall Street Target Price | 2.03 |
Profit Margin | 0.0% |
Operating Margin TTM | -122.32% |
Return On Assets TTM | -12.07% |
Return On Equity TTM | -222.04% |
Revenue TTM | 510.0M |
Revenue Per Share TTM | 2.12 |
Quarterly Revenue Growth YOY | -5.1% |
Gross Profit TTM | 99.0M |
EBITDA | -480.0M |
Diluted Eps TTM | -12.73 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.41 |
EPS Estimate Next Year | -1.17 |
EPS Estimate Current Quarter | -0.39 |
EPS Estimate Next Quarter | -0.36 |
What analysts predicted
Upside of 72.03%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 68.2M | ↑ 172.36% |
Net Income | -123.4M | ↑ 23.06% |
Net Profit Margin | -180.85% | ↑ 219.41% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 147.7M | ↑ 116.5% |
Net Income | -129.4M | ↑ 4.84% |
Net Profit Margin | -87.58% | ↑ 93.27% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 216.8M | ↑ 46.8% |
Net Income | -242.0M | ↑ 87.06% |
Net Profit Margin | -111.6% | ↓ 24.02% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 279.6M | ↑ 28.95% |
Net Income | -602.2M | ↑ 148.87% |
Net Profit Margin | -215.37% | ↓ 103.77% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 460.4M | ↑ 64.68% |
Net Income | -379.0M | ↓ 37.06% |
Net Profit Margin | -82.31% | ↑ 133.06% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 516.3M | ↑ 12.13% |
Net Income | -3.1B | ↑ 719.59% |
Net Profit Margin | -601.64% | ↓ 519.33% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 126.1M | ↑ 10.25% |
Net Income | -205.1M | ↑ 3.51% |
Net Profit Margin | -162.64% | ↑ 10.6% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 123.7M | ↓ 1.93% |
Net Income | -181.9M | ↓ 11.34% |
Net Profit Margin | -147.03% | ↑ 15.61% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 136.6M | ↑ 10.45% |
Net Income | -2.5B | ↑ 1287.59% |
Net Profit Margin | -1.8K% | ↓ 1700.01% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 133.5M | ↓ 2.26% |
Net Income | -301.2M | ↓ 88.07% |
Net Profit Margin | -225.52% | ↑ 1621.52% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 122.5M | ↓ 8.3% |
Net Income | -99.8M | ↓ 66.86% |
Net Profit Margin | -81.51% | ↑ 144.01% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 117.4M | ↓ 4.16% |
Net Income | -192.2M | ↑ 92.54% |
Net Profit Margin | -163.76% | ↓ 82.25% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 211.1M | ↑ 61.56% |
Total Liabilities | 89.3M | ↑ 182.75% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 283.0M | ↑ 34.05% |
Total Liabilities | 121.1M | ↑ 35.66% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 781.6M | ↑ 176.22% |
Total Liabilities | 402.0M | ↑ 231.87% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 3.4B | ↑ 338.9% |
Total Liabilities | 1.5B | ↑ 261.77% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 43.41% |
Total Liabilities | 1.9B | ↑ 33.49% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.0B | ↓ 60.28% |
Total Liabilities | 1.9B | ↓ 4.58% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 4.9B | ↓ 2.99% |
Total Liabilities | 1.9B | ↓ 1.18% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 4.8B | ↓ 3.09% |
Total Liabilities | 1.9B | ↓ 0.89% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↓ 51.96% |
Total Liabilities | 1.9B | ↓ 1.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 11.54% |
Total Liabilities | 1.9B | ↓ 1.95% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.0B | ↓ 3.56% |
Total Liabilities | 1.9B | ↓ 0.81% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.7B | ↓ 13.43% |
Total Liabilities | 1.7B | ↓ 6.69% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -98.0M | ↑ 28.39% |
Investing Cash Flow | -37.0M | ↓ 328.18% |
Financing Cash Flow | 80.9M | ↑ 50.57% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -92.2M | ↓ 5.88% |
Investing Cash Flow | 35.8M | ↓ 196.81% |
Financing Cash Flow | 157.2M | ↑ 94.32% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -145.1M | ↑ 57.29% |
Investing Cash Flow | -280.3M | ↓ 883.58% |
Financing Cash Flow | 464.8M | ↑ 195.75% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -298.5M | ↑ 105.79% |
Investing Cash Flow | -400.6M | ↑ 42.91% |
Financing Cash Flow | 673.0M | ↑ 44.8% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -559.8M | ↑ 87.54% |
Investing Cash Flow | -204.1M | ↓ 49.05% |
Financing Cash Flow | 1.6B | ↑ 132.68% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -175.9M | ↑ 6.58% |
Investing Cash Flow | 170.5M | ↓ 938.92% |
Financing Cash Flow | 7.0M | ↓ 1056.6% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -147.5M | ↓ 16.13% |
Investing Cash Flow | -449.5M | ↓ 363.61% |
Financing Cash Flow | -920.0K | ↓ 113.08% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -134.7M | ↓ 8.71% |
Investing Cash Flow | 109.0M | ↓ 124.24% |
Financing Cash Flow | 3.8M | ↓ 509.78% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -128.7M | ↓ 4.45% |
Investing Cash Flow | 43.8M | ↓ 59.81% |
Financing Cash Flow | -1.7M | ↓ 144.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.4M | ↓ 58.07% |
Investing Cash Flow | 73.9M | - |
Financing Cash Flow | -135.8M | ↓ 22765.78% |
Sell
Neutral
Buy
Invitae Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Invitae Corporation | -20.81% | -49.14% | -51.24% | -93.31% | -85.03% |
![]() Idexx Laboratories, Inc. | -7.04% | 6.58% | 30.38% | 40.09% | 103.99% |
![]() Agilent Technologies Inc. | -9.58% | -25.46% | -3.96% | 28.93% | 75.09% |
![]() Thermo Fisher Scientific, Inc. | -2.87% | -8.71% | -1.65% | 46.88% | 138.42% |
![]() Danaher Corp. | 0.83% | -13.94% | -6.41% | 36.3% | 127.98% |
![]() Iqvia Holdings Inc. | 9.84% | -3.07% | -0.38% | 40.36% | 98.32% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Invitae Corporation | NA | NA | -0.51 | -1.41 | -2.22 | -0.12 | 0.0 | -0.14 |
![]() Idexx Laboratories, Inc. | 55.24 | 55.24 | 7.21 | 9.69 | 0.94 | 0.22 | 0.0 | 10.13 |
![]() Agilent Technologies Inc. | 26.6 | 26.6 | 2.36 | 5.61 | 24.78 | 0.1 | 0.01 | 19.58 |
![]() Thermo Fisher Scientific, Inc. | 28.89 | 28.89 | 4.28 | 23.71 | 14.48 | 0.05 | 0.0 | 109.55 |
![]() Danaher Corp. | 25.34 | 25.34 | 3.24 | 8.79 | 0.14 | 0.06 | 0.0 | 68.31 |
![]() Iqvia Holdings Inc. | 35.29 | 35.29 | 1.48 | 10.42 | 17.8 | 0.05 | 0.0 | 31.98 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Invitae Corporation | Hold | $328.6M | -85.03% | NA | 0.0% |
![]() Idexx Laboratories, Inc. | Buy | $37.6B | 103.99% | 55.24 | 20.38% |
![]() Agilent Technologies Inc. | Buy | $34.4B | 75.09% | 26.6 | 19.19% |
![]() Thermo Fisher Scientific, Inc. | Buy | $200.9B | 138.42% | 28.89 | 13.75% |
![]() Danaher Corp. | Buy | $173.7B | 127.98% | 25.34 | 22.4% |
![]() Iqvia Holdings Inc. | Buy | $38.3B | 98.32% | 35.29 | 7.28% |
ARK Investment Management LLC
BlackRock Inc
Vanguard Group Inc
Nikko Asset Management Americas Inc
Sumitomo Mitsui Trust Holdings Inc
Deerfield Management Co
Invitae Corporation’s price-to-earnings ratio stands at None
Read Moreinvitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people. specializing in genetic diagnostics for hereditary disorders, invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today. choose from our curated panels or design your own test for the same low price. today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. together we can improve healthcare for billions of people.
Organization | Invitae Corporation |
Employees | 1700 |
CEO | Mr. Kenneth D. Knight |
Industry | Health Services |
Smart For Life Inc
$1.14
-2.56%
Paysign, Inc.
$2.64
+2.33%
Novavax, Inc.
$7.47
-2.86%
Silvercrest Metals Inc
$6.27
-2.18%
Fidelity U.s. Multifactor Etf
$25.43
-0.04%
Proshares Ultrapro Dow30 Etf
$57.69
+0.47%
Invesco Dynamic Large Cap Va
$45.62
-0.02%
Blackrock Municipal Income Quality Trust
$11.15
+0.18%
Tupperware Brands Corporation
$0.86
+0.83%